DSIP vs Melatonin: An Honest Comparison

What are we actually comparing?

Melatonin is a hormone your pineal gland produces in response to darkness. In the US it is sold as a dietary supplement, not as an FDA-approved drug, though FDA-approved melatonin receptor agonists (like ramelteon) exist as a separate prescription class and are outside the scope of this comparison.

DSIP, also called emideltide, is a synthetic nonapeptide first described in the 1970s and studied intermittently since, mostly outside the United States. It is sold in the research-chemical and compounding gray market, not as an approved drug or a regulated supplement. If you want the fuller regulatory picture, see the FDA Peptide Status Tracker and our dedicated page on DSIP's FDA status in 2026.

Regulatory status: two different worlds

Melatonin's OTC availability rests on its supplement classification, which is a separate legal track from drug approval and does not require the FDA to have found it safe and effective for any specific sleep condition.

DSIP's regulatory position is thinner. Per the FDA's Category 2 bulk drug substances list (content current 04/22/2026), DSIP's nomination for the 503A compounding bulks list was withdrawn by the nominators. Withdrawal is not the same as approval or a favorable safety finding; it simply means the nomination is no longer active. DSIP is not on the 503A bulks list, and no enforcement discretion currently covers compounding it under the FDA's 503A bulk substances framework. At the July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee, the committee voted against recommending emideltide (DSIP) for that list. That is a rejection, not a pending approval, and it should not be read as regulatory momentum toward legal compounded DSIP.

What does the human evidence show for each?

A full sourced review of melatonin's trial base is outside this page, and readers should not take any implied number here as a citation. What can be said honestly: melatonin has been studied in far more, and far more recent, human trials than DSIP, and it sits inside mainstream sleep-medicine discussion in a way DSIP does not. Readers wanting DSIP-specific sleep data should see DSIP for sleep: what the evidence actually shows.

DSIP's human data is sparse and old. A 1992 double-blind study in chronic insomniac patients reported some sleep effects, but it is a single small trial from over three decades ago. A 2009 study using DSIP as an anesthesia adjunct looked at EEG, bispectral index, and heart rate variability changes during isoflurane anesthesia, not spontaneous sleep. An earlier 1989 study found DSIP reduced circulating ACTH after intravenous injection, which is a hormonal observation, not a sleep-quality endpoint. A 1989 review on the concept of insomnia discusses DSIP only in a background, conceptual sense.

Much of the rest of the DSIP literature is animal research: rat studies on aging-related metabolic effects, antioxidant enzyme expression, mitochondrial electron transport, lysosomal membrane function, and hippocampal neuronal activity. These are mechanistic and preclinical. They describe biological plausibility, not demonstrated human benefit.

Where the evidence gets overstated

A recurring problem in DSIP marketing is conflating DSIP itself with related but distinct formulations studied mainly in Russian and Ukrainian literature: deltaran, deltalycin, deltalicin, and the peptide KND. Studies on deltaran and melatonin in an experimental dermatitis model, deltalycin in diabetic retinopathy, deltalicin in diabetic retinopathy, and KND as a putative endogenous DSIP prototype are sometimes cited as if they were direct DSIP human trials. They are not. Treating an analog's outcome as DSIP's outcome overstates what is known. A Russian-language study on stress-modulating therapy in chronic brain ischemia has similar limits: narrow population, older methodology, and no independent replication in a US or EU regulatory context.

There is also basic pharmacology worth naming plainly. Peptides generally have limited and variable ability to cross the blood-brain barrier, a point discussed generally in the blood-brain barrier peptide literature. This matters for any peptide marketed for a central nervous system effect like sleep, since route of administration and delivery form materially affect whether a peptide reaches its proposed site of action at all.

A structured way to compare the two

Use this table as a screen, not a verdict. If a source or vendor claims DSIP has "clinical trial support," ask which specific study, in which population, using which formulation, before accepting the claim.

Safety and practical considerations

DSIP's side effect profile in humans is not well characterized because the human trial base is so limited; see DSIP side effects and safety for what little is documented. Because it is not an approved drug or a regulated supplement, there is no standardized manufacturing, dosing, or purity oversight for products sold as DSIP, which is a distinct risk layer separate from the peptide's own biology.

This page cannot provide individualized dosing guidance for either substance, and anyone with a diagnosed sleep disorder, adrenal or endocrine condition, or who is on other sedating medications should discuss options with a clinician rather than self-select between an OTC supplement and an unregulated peptide. Sudden new neurological symptoms, chest pain, severe confusion, or breathing difficulty after taking any substance warrant urgent medical evaluation, not a comparison of supplement labels.

The honest bottom line

What is established: melatonin is a legally available OTC supplement in the US with a substantial human research history; DSIP has no FDA-approved use and was recently rejected for legal compounding status. What is plausible but unproven: DSIP may have some biological effect on sleep architecture, based on limited older human data and animal mechanistic work. What is not established: that DSIP is a safe, effective, or regulator-recognized alternative to melatonin for any sleep condition. Readers deciding between the two are not choosing between equals, they are choosing between a well-documented OTC supplement and a peptide sitting outside the current US regulatory system. For background on DSIP's mechanism and history, see what DSIP is and DSIP's clinical trial history.